EMBC DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Embecta Investors of Securities Class Action Lawsuit Deadline on August 17, 2026

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Embecta To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Embecta between November 25, 2025 and May 4, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310) .

Faruqi & Faruqi, LLP , a leading national securities law firm, is investigating potential claims against Embecta Corp. ("Embecta" or the "Company") (NASDAQ: EMBC) and reminds investors of the August 17, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: Embecta knew or recklessly disregarded that the Company's guidance was misleading and unattainable. In fact, Embecta touted the Company's pen needle business as "incredibly resolute" mere weeks prior to missing expectations and cutting 2026 fiscal guidance. On May 5, 2026, Embecta published second quarter 2026 fiscal results disclosing that the Company failed to meet its guidance for second quarter 2026 and lowered fiscal year 2026 guidance. In particular, Embecta revealed that revenue declined over 14%, much higher than the guidance of flat to a decline of 2% and that the Company was lowering estimates on US performance, largely in part due to weakness in its pen needle sales. Following this news, the price of Embecta's common stock declined dramatically. From a closing market price of $9.25 per share on May 4, 2026, Embecta's stock price fell to $3.90 per share on May 5, 2026, a decline of over 57.8% in a single day.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.

Faruqi & Faruqi, LLP also encourages anyone with information regarding Embecta's conduct to contact the firm, including whistleblowers, former employees, shareholders and others. To learn more about the Embecta class action, go to www.faruqilaw.com/[EMBC](/en/us/EMBC) or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310) .

What is the Embecta securities fraud lawsuit about? Faruqi & Faruqi, LLP has filed a securities class action lawsuit alleging that Embecta Corp. (NASDAQ: EMBC) and certain of its officers and directors made materially false and misleading statements to investors during the Class Period. The lawsuit alleges that defendants concealed adverse facts concerning the true state of Embecta's financial results and that the Company's publicly issued guidance was misleading and allegedly unattainable. Specifically, the complaint alleges that Embecta touted its pen needle business as "incredibly resolute" just weeks before the Company missed its own guidance and was forced to cut its fiscal year 2026 outlook. On May 5, 2026, Embec...